about
Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits.Coordination of an array of signaling proteins through homo- and heteromeric interactions between PDZ domains and target proteinsThe role of genetic markers in the management of prostate cancer.Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6.Hyperphosphorylation of the BARD1 tumor suppressor in mitotic cells.Lack of PTEN sequesters CHK1 and initiates genetic instability.Ubiquitination and proteasomal degradation of the BRCA1 tumor suppressor is regulated during cell cycle progression.Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.Tumor fraction in cell-free DNA as a biomarker in prostate cancerA dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancerStructural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome SequencingATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate CancerSensitive detection of minimal residual disease in patients treated for early-stage breast cancerCompound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate CancerEvaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized TrialRetinoblastoma Loss in Cancer: Casting a Wider NetA phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer
P50
Q33667666-5BD5C5F3-69B5-4BE2-B14E-9B2567CDA490Q35206829-0D6692F1-99D2-4A4E-86DA-29B5CE07D814Q36256280-A4EF9581-6F39-47C7-BCDA-8CEDB3DACF73Q38018444-40B7E371-63AE-40F8-A52D-9EEC656B5E23Q38728375-59EB5D44-31A7-498C-98BA-9B9C2CEE529EQ40430437-21893286-1AFD-4E52-B1FF-05A641018501Q40458578-ACC060AF-8B9A-47A2-9E59-3C45D79096B2Q40551207-3B13C32C-FF49-4063-BEBD-B11BF0C50863Q43045850-23759223-B8D6-4E4B-81CE-38B0D97D1C02Q47214510-E1F93246-D2C7-4469-91EF-FE377D568570Q58617288-DD2CEB4A-1540-4476-9F97-3F43DA1790A4Q89037460-49213CB4-E114-44FD-AB6B-FA102EC28E8FQ89128842-78194681-1952-4A35-B61D-AB84691727EFQ90006433-AFDB92D0-5F31-4497-9A33-85486205DAA8Q90316165-BDA3029F-9264-4D17-888F-C83CB0E0058AQ90552274-AED02D9D-C459-4391-9AB0-C129160E859AQ91690734-4E073AA3-C963-4B43-A31E-6B23DCD4BC27Q92124745-0B37ED99-C6A1-4238-860A-6CDF4616A7D3Q93069401-AF6216D5-6746-42DF-A3CE-11093C800D6E
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-9344-6631
@en
name
Atish D Choudhury
@ast
Atish D Choudhury
@en
Atish D Choudhury
@es
Atish D Choudhury
@nl
type
label
Atish D Choudhury
@ast
Atish D Choudhury
@en
Atish D Choudhury
@es
Atish D Choudhury
@nl
prefLabel
Atish D Choudhury
@ast
Atish D Choudhury
@en
Atish D Choudhury
@es
Atish D Choudhury
@nl
P106
P1153
8734857600
P31
P496
0000-0001-9344-6631